M. Zamboni (Rio De Janeiro, Brazil), P. Zarogoulidis (Thessaloniki, Greece), T. Blum (Berlin, Germany)
Metabolic modification as a potential therapeutics approach in lung cancer
M. Ilouze, T. Feinberg, R. Shavit, N. Peled (Ramat-Gan, Israel)
|   |
Interleukin 27 (IL27) as a novel therapeutic tool in lung cancer immune therapy
T. Wandtke, M. Jankowski, E. Wedrowska, K. Szablowska, J. Golinska, J. Wielikdzien, J. Kowalewski, P. Kopinski (Bydgoszcz, Poland)
| |
Clinical outcome of S-1 monotherapy in patients with advanced non-small cell lung cancer after treatment of pemetrexed
M. Kawaishi, H. Wakui, Y. Yoshii, K. Kobayashi, S. Ito, N. Takasaka, J. Kojima, T. Ishikawa, K. Shimizu, T. Numata, H. Hara, K. Saito, Y. Kaneko, J. Araya, K. Nakayama, K. Kuwano (Tokyo, Japan)
| |
Approach to hypersensitivity reactions to chemotherapeutics in patients with lung cancer
O. Goksel, T. Goksel, G. Cok, H. Karakus, M. Erdinc (Izmir, Turkey)
| |
Efficacy and safety of full oral vinorelbine (NVBO) on D1 and D8 with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer (NSCLC) patients: Results of a prospective study in nonrandomized population of 259 patients
J. Skrickova, B. Kadlec, O. Venclicek, T. Janaskova, V. Kolek, I. Grygarkova, H. Coupkova, P. Reiterer (Brno, Ostrava, Olomouc, Usti Nad Labem, Czech Republic)
| |
High pretreatment plasma VEGF level is associated with shorter survival in paclitaxel-carboplatin treated non-small cell lung carcinoma patients
Z. Weiszhar, I. Horvath, G. Losonczy, G. Galffy (Budapest, Hungary)
| |
Is there a difference in response to first line chemotherapy related to age in patients with locally advanced or metastatic non-small lung cancer?
S. Badovinac, M. Korsic, D. Capalija, B. Cucevic, L. Pavlovic, M. Roglic (Zagreb, Croatia)
| |
Anticancer chemotherapy combined with anti-tuberculosis treatment: A systematic review
A. Christopoulos, I. Katsarou, I. Christopoulos (Athens, Zakynthos, Greece)
| |
Bevacizumab (Bv) in elderly pts with NSCLC: Experience at a tertiary referral center
D. Vassos, S. Tsagouli, M. Zontanos, A. Vassias, S. Tsimpoukis, P. Boura, A. Charpidou, K. Syrigos (Athens, Greece)
| |
Single agent gemcitabine or docetaxel in the second-line therapy for patients with non-small cell lung cancer previously treated with platin-based chemotherapy
A. Yurdakul, F. Yildirim, A. Baha, C. Öztürk (Ankara, Turkey)
| |
A single centre review of palliative chemotherapy in newly diagnosed stage IIIb and IV lung cancer patients with good performance status
A. Ewence, A. Higton (Frimley, United Kingdom)
| |
Chemotherapy in elderly patients with non-small-cell lung cancer in Tunisian respiratory department
H. Kamoun, D. Greb, S. Fenniche, L. Fekih, H. Ben Abdelghaffar, H. Smadhi, I. Akrout, H. Hassen, M. L. Megdiche (Ariana, Tunisia)
| |
Clinical profile of newly diagnosed patients of non small cell carcinima with epidermal growth factor receptor positivity on oral tyrosine kinase inhibitor therapy
U. Vijai Kumar, V. K. Ratnavelu, B. Vaswani (Hyderabad, India)
| |
EGFR frequency and response to chemotherapy in a Brazilian NSCLC population
H. Naemi Honma, M. de Toledo Leme, E. Mello De Capitani, M. Wesley Perroud, A. de Souza Barbeiro, A. P. Salles Perroud, I. Felizardo Toro, R. Kalaf Mussi, J. Cláudio Seabra, J. Vassallo, A. Morcillo, D. Botelho Costa, L. Zambon (Campinas, Brazil; Boston, United States Of America)
| |
Poor prognostic factors in advanced pulmonary adenocarcinoma patients receiving first-line gefitinib
T. Y. Kuo, M. J. Tsai, Y. H. Tsai, C. M. Chen, W. A. Chang, P. J. Wei, C. J. Yang, M. S. Huang (Kaohsiung, Taiwan)
| |
ERCC1 and MDR1 expression and polymorphism frequency related to clinical outcome and chemotherapy response in a Brazilian sample of NSCLC patients
L. Zambon, A. P. Salles Perroud, M. Toledo Leme, E. Mello De Capitani, M. Wesley Perroud, Jr., A. Souza Barbeiro, B. Alonso Saad, J. Vassalo, A. Morcillo, D. Botelho Costa, H. Naemi Honma (Campinas, Brazil; Boston, United States Of America)
| |
FACT-L (functional assessment of cancer therapy-lung) psychometric properties of the Turkish version of quality of life scale (validity and reliability) and determination using the clinic (Akkaya-1 project)
B. Basarik, T. Göksel, A. E. Erbaycu, E. Eser, A. Öz, P. çelik, K. Kiyar Gürsul, E. çakir Ediz, O. Hatipoglu, B. Atay Yayla, S. Baser, H. Baydur (Izmir, Manisa, Edirne, Denizli, Turkey)
| |
The effect of changes in quality of life in patients with lung cancer in the observation period (European Organization for Research and treatment of Cancer) EORTC QLQ-C 30 results of the evaluation and follow-up (AKAYAK-1 project)
A. Öz, P. çelik, T. Göksel, A. E. Erbaycu, E. Eser, B. Basarik, K. Kiyar Gürsul, E. çakir Ediz, O. Hatipoglu, B. Atay Yayla, S. Baser, H. Baydur (Manisa, Izmir, Edirne, Denizli, Turkey)
| |
The assessment of the effect of changes in lung cancer follow-up period to the quality of life by using EQ-5D questionnaire and follow data (the project of AKAYAK-1)
K. Kiyar Gursul, A. Emin Erbaycu, T. Goksel, E. Eser, B. Basarik, A. Oz, P. Celik, E. Cakir Ediz, O. Hatipoglu, B. Atay Yayla, S. Baser, H. Baydur (Izmir, Manisa, Edirne, Denizli, Turkey)
| |
Experiences of lung-cancer care- perspectives of patients and significant others
A. Bettembourg Grundström, K. Andersson, B. Göthman, E. Österlund Efraimsson (Falun, Sweden)
| |